Download full-text PDF |
Source |
---|
J Nephrol
January 2025
School of Nursing, Curtin University, Kent Street, Bentley, WA, 6102, Australia.
Background: Advanced chronic kidney disease is a life-limiting disease that is known to benefit from palliative care. Unmet palliative care need in patients with kidney failure is commonly reported but the level of need among patients receiving haemodialysis is unknown.
Methods: A period prevalence study of adult patients attending two hospital-based dialysis units was conducted.
Psychother Res
December 2024
Department of Psychiatry, University of British Columbia, Vancouver, Canada.
Objective: The tendency to linguistically synchronize is an adaptive and prosocial process observed in verbal and written communication. Research in therapeutic contexts has primarily conceptualized reciprocal language style matching (rLSM; i.e.
View Article and Find Full Text PDFBioinformatics
November 2024
Department of Artificial Intelligence, Beijing Key Lab of Traffic Data Analysis and Mining, School of Computer Science & Technology, Beijing Jiaotong University, Beijing 100044, China.
Motivation: Drug repositioning (DR), identifying novel indications for approved drugs, is a cost-effective strategy in drug discovery. Despite numerous proposed DR models, integrating network-based features, differential gene expression, and chemical structures for high-performance DR remains challenging.
Results: We propose a comprehensive deep pretraining and fine-tuning framework for DR, termed DrugRepPT.
Medicine (Baltimore)
November 2024
Department of Geriatrics, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
J Immunother Cancer
November 2024
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
Background: Higher cytotoxic T lymphocyte (CTL) numbers in the tumor microenvironment (TME) predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and positive long-term outcomes in triple-negative breast cancer (TNBC). pCR to NAC is achieved only in 30-40% of patients. The combination of NAC with pembrolizumab increases the pCR rate but at the cost of immune-related adverse events (irAEs).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!